СЕНТРО ДЕ ИНХЕНЬЕРИЯ ХЕНЕТИКА И БИОТЕКНОЛОХИЯ (CU)
发明人:
ПЕНТОН РОЛЬ Хиселье (CU),ЛЛОПИС АРСУАГА Алексей (CU),МАРИН ПРИДА Хавьер (CU),ПЕНТОН АРИАС Эдуардо (CU),РОДРИГЕС ХИМЕНЕС Эфраин (CU),МУСАКЧИО ЛАСА Алексис (CU),БЕСАДА ПЕРЕС Владимир Армандо (CU),ПАРДО
申请号：
RU2014103246/04
公开号：
RU2014103246A
申请日:
2012.06.29
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. Chromogenic peptides (PCB-aa) with sequences of 3-6 amino acids containing a phycocyanobilin structure characterized by its amino acid sequence, selected from the group consisting of sequences identified as SEQ ID NO: 1 - SEQ ID NO: 5.2. A pharmaceutical composition, characterized in that it comprises at least one of the chromogenic peptides (PCB-aa) according to claim 1 and acceptable pharmaceutical excipients. The pharmaceutical composition according to claim 2, characterized in that it covers at least one of the chromogenic peptides (PCB-aa) that are contained in SEQ ID NO: 1 - SEQ ID NO: 5, in the range of 0.9-3.375 mg and pharmaceutically acceptable excipients for the prevention and treatment of ischemic and neurodegenerative diseases. 4. A compound selected from the group formed by the peptides of claim 1, identified as SEQ ID NO: 1 to SEQ ID NO: 5, and phycocyanobilin, for the prevention or treatment of ischemia or brain degeneration. 5. The use of the compound of claim 4 for the manufacture of a medicament for the prophylaxis or treatment of diseases of the central nervous system (CNS) that progress with ischemic, inflammatory or neurodegenerative damage. A method for the prophylaxis or treatment of ischemia or tissue degeneration, wherein a pharmaceutical composition is administered, which comprises at least one compound according to claim 4.7. The method of claim 6, wherein ischemia or tissue degeneration leads to CNS diseases that progress with ischemic, inflammatory, or neurodegenerative damage. A pharmaceutical combination, characterized in that its components produce a synergistic effect, and including the first1. Хромогенные пептиды (PCB-aa) с последовательностями из 3-6 аминокислот, содержащие фикоцианобилиновую структуру, характеризуемую ее аминокислотной последовательностью, выбранные из группы, состоящей из последовательностей, идентифицированных как SEQ ID NO: 1 - SEQ ID NO: 5.2. Фармацевтическая композиция, отличающаяся тем, что она включает
